Advertisement

Topics

TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With The FDA For A Phase III Program Of TG-1101 (Ublituximab) For Patients With Multiple Sclerosis (MS)

20:00 EDT 31 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With The FDA For A Phase III Program Of TG-1101 (Ublituximab) For Patients With Multiple Sclerosis (MS)

NEXT ARTICLE

More From BioPortfolio on "TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With The FDA For A Phase III Program Of TG-1101 (Ublituximab) For Patients With Multiple Sclerosis (MS)"

Quick Search
Advertisement